Publications by authors named "C Ellervik"

Objectives: To test whether haemochromatosis C282Y homozygotes have increased risk of diabetes, liver disease, and heart disease even when they have normal plasma iron, transferrin saturation, or ferritin concentrations and to test whether C282Y homozygotes with diabetes, liver disease, or heart disease have increased mortality compared with non-carriers with these diseases.

Design: Prospective cohort study.

Setting: Three Danish general population cohorts: the Copenhagen City Heart Study, the Copenhagen General Population Study, and the Danish General Suburban Population Study.

View Article and Find Full Text PDF

Purpose: Cardiovascular autonomic neuropathy (CAN) is a common diabetic complication associated with excess morbidity and mortality. CAN is also seen in conditions such as Parkinson's disease. Normative reference data for cardiovascular autonomic function are used to stratify individuals into those with and without CAN.

View Article and Find Full Text PDF

Previous Mendelian randomization (MR) studies showed an association between hypothyroidism and cataract and between high-normal free thyroxine (FT4) and late age-related macular degeneration (AMD), but not between FT4, thyroid stimulating hormone (TSH), or hyperthyroidism and diabetic retinopathy or cataract. These studies included a limited number of genetic variants for thyroid function and did not investigate autoimmune thyroid disease (AITD) or glaucoma, include bidirectional and multivariable MR (MVMR), and examine sex differences or potential mediation effects of diabetes. We aimed to address this knowledge gap.

View Article and Find Full Text PDF
Article Synopsis
  • The COMBI II clinical trial evaluated the safety and efficacy of combining ruxolitinib and low-dose pegylated interferon alfa-2a in 25 patients with newly diagnosed polycythemia vera (PV) over two years.
  • The results showed a high peripheral blood cell count remission rate of 92% and 56% of patients meeting remission criteria, with notable improvements in symptoms like abdominal discomfort and night sweats.
  • Additionally, the treatment significantly decreased the JAK2V617F variant allele frequency, with 60% of patients achieving molecular remission, indicating effective outcomes with manageable toxicity.
View Article and Find Full Text PDF